Caspases — cysteinyl aspartate-specific proteases — are the enzymes that actually execute programmed cell death, and, in a separate inflammatory branch, mature the pro-forms of interleukin-1β and interleukin-18. In humans roughly a dozen caspases split into two functional classes: the apoptotic caspases, themselves divided into initiators and executioners, and the inflammatory caspases. They sit at the center of the questions researchers most often type into a search bar: why is cleaved caspase-3 treated as the gold-standard apoptosis marker, what does caspase-8 do beyond death-receptor signaling, how does caspase-1 cause pyroptosis, and — the practical one — how do you measure caspase activation without mistaking one family member for another? Their dysregulation threads through cancer (evasion of apoptosis), neurodegeneration, autoinflammatory disease, and ischemia–reperfusion injury, which is why the family has stayed a high-traffic research topic for three decades.

Quantifying these enzymes — as active enzyme, as their proteolytically cleaved fragment, or as substrate-cleaving activity — requires reagents matched to the exact question. Our portfolio covers ELISA kits for cleaved or active caspase-3, caspase-8, and caspase-9, matched antibody pairs for custom immunoassay development, and fluorometric and colorimetric activity-assay components built on the canonical recognition motifs (for example DEVD, IETD, LEHD, and YVAD substrates) for orthogonal validation. For laboratories profiling the full apoptotic cascade we supply validated capture and detection antibodies engineered to separate closely related executioner caspases that share cleavage specificity, so a single study can track initiator and executioner engagement without changing platforms.

Browse More Caspases Products

The Caspase Family: Initiators, Executioners, and Inflammatory Enzymes

Every caspase is synthesized as an inactive zymogen — a pro-caspase — composed of an N-terminal prodomain, a large subunit, and a small subunit. The prodomain length and its recruited-domain type define the class. Initiator caspases (caspase-2, -8, -9, -10) carry long prodomains bearing death-effector domains (DEDs) or caspase-recruitment domains (CARDs) that concentrate them into activation platforms: the death-inducing signaling complex at death receptors, the apoptosome in the mitochondrial pathway, and the inflammasome. Executioner caspases (caspase-3, -6, -7) have short prodomains and are activated by initiators, then dismantle the cell by cleaving hundreds of substrates. Inflammatory caspases (caspase-1, -4, -5, -11, -12, -14) lack the canonical death-execution role and instead process cytokines and the pore-forming protein GSDMD. This tripartite organization is precisely why a single phrase like "caspase assay" can mean very different things depending on whether you measured activity, cleaved fragment, or cytokine output.

Figure 1. Schematic representation of intrinsic and extrinsic apoptotic pathways. (Source: Wang M, et al. 2026)

Caspase-3 — The Executioner Hallmark

Caspase-3 is the most studied member of the family and the enzyme whose cleavage is the canonical biochemical signature of apoptosis. Once activated by initiator caspases it proteolyzes structural and repair proteins — among them PARP, ICAD, lamin, and cytokeratins — producing the membrane blebbing and DNA fragmentation that define the apoptotic morphology. In practice, "cleaved caspase-3" detected by immunoassay or western blot is the marker most clinicians and basic researchers reach for when they ask "is my cell or tissue undergoing apoptosis." Its activity, not merely its abundance, tracks death kinetics, which is why activity assays and cleavage-based ELISAs are used as complementary rather than interchangeable readouts. Aberrantly low caspase-3 activation is a recurring hallmark of therapy-resistant tumors, making it both a death-execution marker and a treatment-response indicator.

Caspase-8 — Extrinsic Initiator and Necroptosis Gatekeeper

Recruited to the death-inducing signaling complex at death receptors such as Fas/CD95 and the TRAIL receptors, caspase-8 initiates extrinsic apoptosis by activating executioner caspases. The nuance users most often search for is its dual role: in several contexts caspase-8 also restrains a parallel lytic program — necroptosis — by cleaving and inactivating the kinase RIPK3 (and, through the c-FLIP long-isoform complex, tuning complex II). When caspase-8 is absent or inhibited, RIPK3 partners with MLKL to drive necroptotic cell death, which is why caspase-8 deficiency causes embryonic lethality and severe autoinflammation in animal models. For anyone asking "why did my cells die if caspase-3 wasn't activated," caspase-8-dependent necroptosis is the leading answer, and it explains why measuring only a caspase-3/7 fragment can miss a death program entirely.

Caspase-9 — Intrinsic / Apoptosome Initiator

Caspase-9 is activated within the apoptosome, a wheel-like complex assembled from apoptotic protease-activating factor 1 (Apaf-1), cytochrome c, and dATP, and it initiates the mitochondrial (intrinsic) pathway triggered by DNA damage, growth-factor withdrawal, or endoplasmic-reticulum stress. Once active it processes the executioner caspases. Because the apoptosome integrates mitochondrial priming, cleaved caspase-9 — together with the upstream release of cytochrome c — is a favored research marker for intrinsic-pathway engagement, conceptually distinct from the extrinsic caspase-8 signal. Distinguishing the two initiators is central to the common experimental question of whether a toxic or therapeutic insult killed cells through the death-receptor route or the mitochondrial route.

Caspase-7 — The Caspase-3 Parallel

Structurally and functionally the closest relative of caspase-3, caspase-7 is also an executioner activated by caspase-8 and caspase-9. It overlaps heavily with caspase-3 in substrate specificity and cellular outcome, which is exactly why many "caspase-3" reagents also capture caspase-7 and why interpreting a pan-executioner signal demands orthogonal confirmation. The two enzymes are not fully redundant at the organism level — their knockout mouse phenotypes differ — but at the level of a DEVD-based activity assay they are effectively indistinguishable, a caveat that matters whenever a study claims caspase-3-specific activation.

Caspase-1 — Inflammatory Sensor and Pyroptosis Driver

The prototypical inflammatory caspase, caspase-1 is activated within inflammasomes — most notably the NLRP3, AIM2, and NLRC4 complexes — in response to pathogens, pore-forming toxins, or crystalline and endogenous danger signals. Active caspase-1 cleaves pro-IL-1β and pro-IL-18 to their secreted forms and, independently, cleaves GSDMD; the N-terminal fragment of GSDMD oligomerizes in the membrane to form pores, the defining event of pyroptosis, an inflammatory lytic death. For users searching "what causes pyroptosis" or "how is IL-1β matured," caspase-1 is the central node. Its activation therefore serves as a biomarker of inflammasome engagement across autoinflammatory and infectious disease, and GSDMD cleavage is now read as the functional signature of the pathway.

Caspase-4 / Caspase-5 (Human) and Caspase-11 (Mouse) — The Non-Canonical Inflammasome

These inflammatory caspases are directly activated by cytosolic lipopolysaccharide binding to their CARD domains, bypassing the need for a canonical sensor complex. This non-canonical inflammasome drives GSDMD cleavage, pyroptosis, and septic tissue injury in Gram-negative infection, and it feeds back to amplify canonical caspase-1 activation through potassium efflux. They are a frequent subject of searches on "LPS-induced pyroptosis" and represent an emerging therapeutic axis distinct from caspase-1, one that explains why some Gram-negative shock models are uncoupled from NLRP3. For biomarker work they are read through the same endpoints — GSDMD cleavage and IL-1β/IL-18 maturation — rather than as isolated protease activity.

Caspases in Disease: From Cancer to Autoinflammation

Cancer cells frequently disable the apoptotic arm — by mutating or downregulating caspase-8, by upregulating inhibitors, or by decoupling death-receptor signaling — which grants survival and therapy resistance; this is why "restoring caspase activation" is a recurring oncology strategy and why cleaved caspase-3 is read as a treatment-response marker in chemo- and immuno-therapy studies. In neurodegeneration, inappropriate executioner-caspase activation contributes to neuronal loss across amyotrophic lateral sclerosis, Alzheimer, and Huntington models, making caspase-3/-6/-7 inhibition a long-studied neuroprotective concept. In inflammatory and autoinflammatory disease, gain-of-function inflammasome mutations that hyperactivate caspase-1 produce syndromes of excessive IL-1β release that are treatable by cytokine-blockade; the non-canonical LPS-sensing caspases drive septic tissue injury. Ischemia–reperfusion (myocardium, brain) activates caspase-3 acutely, and circulating cleaved caspase-3 has been explored as a tissue-injury biomarker, though pre-analytical stability and cellular source specificity remain active questions that determine whether the signal reflects death in the target organ or spillover from circulating cells.

Measurement Considerations: Activity Assay vs Cleavage-Based Immunoassay

Practical assay note: Before ordering or interpreting any caspase result, confirm what was actually measured. An activity assay using a fluorometric or colorimetric tetrapeptide substrate (for example DEVD-based for executioner caspases, IETD-based for caspase-8, LEHD-based for caspase-9, YVAD-based for caspase-1, LEVD-based for caspase-4, WEHD-based for caspase-5) reports enzyme turnover in a cell or tissue lysate and is the most direct functional readout — but it is vulnerable to lysate preparation, freeze–thaw cycles, and competing proteases, and the synthetic motif preference does not cleanly map to in-vivo substrate specificity. A cleavage-based immunoassay (cleaved caspase-3, -8, or -9 by ELISA or western) reports the proteolytically processed protein and is more stable and specific, but it captures a snapshot of completed cleavage rather than the current rate. Executioner assays often cannot separate caspase-3 from caspase-7 without a motif-specific or antibody-based separation. Normalize activity to protein or cell number, and use fresh or properly snap-frozen material, because caspases autoactivate during mishandling.

For the inflammatory caspases the functional endpoint is usually cytokine maturation (IL-1β / IL-18 ELISA) or GSDMD cleavage rather than the protease alone, and the non-canonical LPS-sensing enzymes are read through those same downstream events. Laboratories developing in-house assays should validate antibody specificity across the caspase family, since the high homology among executioners — especially caspase-3 and caspase-7, but also caspase-6 — produces cross-reactivity that silently inflates apparent signals. Pairing an activity assay with a cleavage-specific immunoassay remains the most defensible way to claim genuine caspase activation, and a time-course (peak activation may fall at three hours or twenty) prevents mistaking a missed window for a negative result.